Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Market

Emerging therapies for Anti-Neutrophil Cytoplasmic Antibody (ANCA)-associated vasculitis, including Depemokimab, FASENRA, and others, are anticipated to drive significant growth in the AAV market in the coming years.

DelveInsight has launched a new report on “Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis – Market Insights, Epidemiology, and Market Forecast-2034” that delivers an in-depth understanding of the ANCA-associated vasculitis, historical and forecasted epidemiology as well as the ANCA-associated vasculitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Explore more about ANCA-associated vasculitis, treatment options, companies working and therapies: https://www.delveinsight.com/report-store/anti-neutrophil-cytoplasmic-antibody-associated-vasculitis-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Some of the key facts of the Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Market Report:

• In June 2024, the FDA cleared a Phase II clinical trial for Ruxoprubart, an investigational therapy for ANCA-associated vasculitis (AAV). The study is designed to assess its ability to reduce dependence on high-dose glucocorticoids and limit related toxicities.

• In 2023, the AAV market across the 7MM was valued at approximately USD 1.5 billion, with strong growth anticipated from pipeline therapies such as Benralizumab (AstraZeneca) and Depemokimab (GlaxoSmithKline). According to DelveInsight, there were an estimated 215,000 diagnosed prevalent cases of AAV in the 7MM that year, with the U.S. leading in case numbers, followed by Japan. Among subtypes, GPA accounted for the highest prevalence, whereas MPA, despite having a higher incidence, showed lower prevalence due to its more severe onset and elevated mortality.

• For relapsing or refractory cases, treatments such as rituximab, NUCALA (mepolizumab; approved for GPA/MPA), and TAVNEOS (avacopan; approved for EGPA) have provided effective alternatives. Notably, TAVNEOS received FDA approval in 2021 as an adjunct therapy for severe GPA and MPA, representing a significant advancement in disease management.

• However, delayed diagnosis remains a major challenge, often leading to poorer outcomes, highlighting the urgent need for early detection strategies and reliable biomarkers in AAV care.

• Leading pharmaceutical companies including GlaxoSmithKline, AstraZeneca, and InflaRx are actively advancing new treatment options. Based on DelveInsight’s patient-based forecast, NUCALA and rituximab dominated the AAV market in the 7MM in 2023. Looking ahead, by 2034, TAVNEOS is projected to generate over USD 1 billion in revenue, becoming the market leader, with FASENRA (benralizumab) expected to outperform Depemokimab among late-stage pipeline therapies.

Key benefits of the Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis market report:

1. ANCA-associated vasculitis market report covers a descriptive overview and comprehensive insight of the ANCA-associated vasculitis Epidemiology and ANCA-associated vasculitis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).

2. The ANCA-associated vasculitis market report provides insights into the current and emerging therapies.

3. The ANCA-associated vasculitis market report provides a global historical and forecasted market covering drug outreach in 7MM.

4. The ANCA-associated vasculitis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the ANCA-associated vasculitis market.

Got queries? Click here to know more about the ANCA-associated vasculitis market landscape https://www.delveinsight.com/sample-request/anti-neutrophil-cytoplasmic-antibody-associated-vasculitis-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Overview

Vasculitides are disorders characterized by inflammation of blood vessel walls, driven by leukocyte activity that causes structural injury. This process can weaken vessel integrity, leading to bleeding, narrowing, or obstruction of the lumen, which in turn may result in tissue ischemia or necrosis. The size, type, and distribution of the affected vessels vary by the form of vasculitis, which may arise as a primary condition or secondary to another disease.

ANCA-associated vasculitis (AAV) represents a group of rare autoimmune diseases of unclear origin, defined by immune cell infiltration and destruction of small blood vessels. These conditions are linked to antineutrophil cytoplasmic antibodies (ANCAs), which target components of neutrophils—most commonly proteinase 3 (PR3) and myeloperoxidase (MPO). The three principal subtypes—granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic GPA (EGPA)—are associated with abnormal immune responses directed against neutrophil granule proteins, particularly PR3 and MPO.

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Market Outlook

Current treatment guidelines for ANCA-associated vasculitis (AAV) emphasize controlling disease activity, preventing relapses, and addressing long-term complications such as organ damage, medication-related toxicities, and increased risks of cardiovascular disease and cancer. Standard management begins with induction therapy, typically using cyclophosphamide or rituximab in combination with glucocorticoids, followed by a maintenance phase with rituximab, azathioprine, or methotrexate, during which glucocorticoids are gradually tapered. Although these regimens are effective at inducing and maintaining remission, they are often associated with notable side effects.

Rituximab is frequently favored for induction therapy due to its efficacy and relatively better safety profile, with common dosing schedules including 375 mg/m² weekly for four weeks or 1,000 mg twice, two weeks apart. Cyclophosphamide remains an important option, particularly in cases where rituximab is less accessible due to cost. While the RAVE trial did not provide long-term outcomes on cancer or survival, newer evidence suggests that rituximab—unlike cyclophosphamide—does not appear to elevate malignancy risk.

Explore how the ANCA-associated vasculitis market is rising in the upcoming years @ https://www.delveinsight.com/report-store/anti-neutrophil-cytoplasmic-antibody-associated-vasculitis-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Marketed Drugs

• TAVNEOS (avacopan): Chemocentryx/Amgen

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Emerging Drugs

• Depemokimab (GSK3511294): GlaxoSmithKline

• FASENRA (benralizumab): AstraZeneca

To know more about the therapies that are driving the ANCA-associated vasculitis treatment market, visit: https://www.delveinsight.com/sample-request/anti-neutrophil-cytoplasmic-antibody-associated-vasculitis-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Scope of the Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Market Report

• Study Period: 2020-2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key ANCA-associated vasculitis Companies: GlaxoSmithKline, AstraZeneca, InflaRx, and others

• Key ANCA-associated vasculitis Therapies: Depemokimab (GSK3511294), FASENRA (benralizumab), TAVNEOS (avacopan), and others

• ANCA-associated vasculitis Therapeutic Assessment: ANCA-associated vasculitis current marketed and ANCA-associated vasculitis emerging therapies

• ANCA-associated vasculitis Market Dynamics: ANCA-associated vasculitis market drivers and ANCA-associated vasculitis market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• ANCA-associated vasculitis Unmet Needs, KOL’s views, Analyst’s views, ANCA-associated vasculitis Market Access and Reimbursement

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. ANCA-associated vasculitis Patient Share (%) Overview at a Glance

5. ANCA-associated vasculitis Market Overview at a Glance

6. ANCA-associated vasculitis Disease Background and Overview

7. ANCA-associated vasculitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

9. Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Current Treatment and Medical Practices

10. Unmet Needs

11. Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Emerging Therapies

12. Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Market Outlook

13. Country-Wise Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Market Analysis (2020–2034)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Click here to read more about Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Market Outlook 2034 @ https://www.delveinsight.com/report-store/anti-neutrophil-cytoplasmic-antibody-associated-vasculitis-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Related Reports:

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Pipeline Insights, DelveInsight

“Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Pipeline Insight, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis market. A detailed picture of the Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis pipeline landscape is provided, including a disease overview and treatment guidelines for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. .

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/